TG Therapeutics (NASDAQ:TGTX) reported the follicular lymphoma (FL) cohort of the its Phase 2b pivotal trial of umbralisib met the primary endpoint of overall response rate (ORR).
The trial included 188 FL patients who received at least one dose of umbralisib, a PI3K delta inhibitor, and who had previously received at least two prior lines of therapy. The trial results met TG’s prespecified ORR target of 40% to 50%.
“There are no fully approved drugs for patients with FL that have progressed following two or more prior lines of therapy and we are excited by the potential to offer a novel treatment for this underserved population,” executive chairman and CEO Michael Weiss said in a statement.
